A
Amylyx Pharmaceutical
Developing new treatments for ALS, Alzheimer's, and all neurodegenerative diseases
About Amylyx Pharmaceutical
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, specifically Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). The company operates in the healthcare sector, targeting patients, caregivers, healthcare providers, and researchers as its primary clients.
Amylyx's flagship product, AMX0035, is under rigorous clinical evaluation. The CENTAUR ALS trial, a 24-week Phase II clinical trial, demonstrated significant treatment benefits for ALS patients. This trial was randomized, double-blind (neither participants nor researchers know who is receiving the treatment), and placebo-controlled (some participants receive a non-active substance to compare results). The positive results from this trial have been published in reputable medical journals, including the New England Journal of Medicine and Muscle Nerve.
Additionally, Amylyx is conducting the PEGASUS trial, which is another randomized, double-blind, placebo-controlled study. This trial focuses on evaluating the safety and effectiveness of AMX0035 in patients with late mild cognitive impairment or early dementia due to Alzheimer's Disease over a 24-week period.
Amylyx's business model revolves around the research and development of innovative treatments, followed by clinical trials to prove their efficacy and safety. Once these treatments are approved by regulatory bodies, the company plans to commercialize them, generating revenue through sales to healthcare providers and patients.
The company also engages in awareness campaigns, such as ALS Awareness Month, to educate the public and unite communities in the fight against these debilitating diseases. This not only helps in spreading awareness but also in building a supportive community around their cause.
In summary, Amylyx Pharmaceuticals is dedicated to advancing treatments for neurodegenerative diseases through rigorous clinical trials and community engagement, aiming to bring effective therapies to market and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2022
Open roles
Amylyx Pharmaceutical in the Cambridge ecosystem
The Amylyx Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Lysosomal Therapeutics
Morningside
ALS Investment Fund- BTBelinda Termeer
Series B and later14 investors entered at this stage
Viking Global Investors
Alpha Wave Global
aMoon Fund
Marshall Wace
Woodline Partners
Rock Springs Capital
Perceptive Advisors- PFPolaris Founders Fund
Bain Capital Life Sciences
Tybourne Capital Management
Avoro Capital Advisors- VMVerition Fund Management
- 6C683 Capital
TCGX
Source: Dealroom Talent Intelligence.
Patents
23 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Amylyx Pharmaceutical on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Amylyx presents full Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia at ObesityWeek
KKR bids $9B for UGI as chip stocks drag Wall Street lower
Amylyx's avexitide hits primary endpoint in Phase 3 LUCIDITY for post-bariatric hypoglycaemia
